Bristol-Myers Squibb (BMY) Earns Coverage Optimism Score of 0.29
News headlines about Bristol-Myers Squibb (NYSE:BMY) have been trending positive recently, Accern reports. The research firm rates the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Bristol-Myers Squibb earned a coverage optimism score of 0.29 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 47.2287780900376 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news stories that may have impacted Accern’s rankings:
- Bristol-Myers Squibb (BMY) versus Veru (VERU) Head to Head Comparison (americanbankingnews.com)
- Investment Grade Analysis On Bristol-Myers Squibb Company (NYSE:BMY) Shares – Collins Courier (collinscourier.com)
- Bristol-Myers Squibb Co (BMY) Industry Group Rank Penalize Rating – Investorplace.com (investorplace.com)
- Sprycel (dasatinib) Added to Standard Chemotherapy Demonstrates Three-Year Survival Benefit in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (finance.yahoo.com)
- Closing Bell Ringer, December 8, 2017 (finance.yahoo.com)
Several brokerages have commented on BMY. BidaskClub upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Saturday, August 12th. Citigroup set a $72.00 price objective on shares of Bristol-Myers Squibb and gave the company a “buy” rating in a report on Tuesday, December 5th. Jefferies Group reiterated a “buy” rating and issued a $72.00 price objective on shares of Bristol-Myers Squibb in a report on Wednesday, September 27th. Vetr downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $63.67 price objective on the stock. in a report on Thursday, September 28th. Finally, Cowen set a $65.00 price objective on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a report on Monday, August 14th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $64.93.
Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The firm had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.20 billion. During the same period in the prior year, the business posted $0.77 earnings per share. Bristol-Myers Squibb’s quarterly revenue was up 6.7% compared to the same quarter last year. research analysts predict that Bristol-Myers Squibb will post 2.99 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, February 1st. Investors of record on Friday, January 5th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Thursday, January 4th. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 annualized dividend and a dividend yield of 2.56%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 61.42%.
In related news, EVP Sandra Leung sold 156,582 shares of the firm’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $63.37, for a total value of $9,922,601.34. Following the completion of the transaction, the executive vice president now directly owns 584,373 shares of the company’s stock, valued at $37,031,717.01. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.23% of the stock is currently owned by company insiders.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.